Overview

Receptor-ligand trafficking and signaling
The family of vascular endothelial growth factors (VEGFs) regulate different aspects of mammalian vascular physiology. The founding member of this family, VEGF-A, is synthesized and secreted as an N-glycosylated homodimer. Most of the downstream effects of VEGF-A bioactivity, such as vascular permeability, cell proliferation, cell migration, cell survival and smooth muscle relaxation, result from binding to the VEGFR2 receptor tyrosine kinase and subsequent activation of downstream signaling pathways (Koch et al., 2011) .
VEGFR2 activation involves trans-autophosphorylation of 6-7 specific cytoplasmic domain tyrosine residues creating phosphotyrosine epitopes e.g. pY1175 (Koch et al., 2011; Roskoski, 2007) . Such post-translational modifications create binding sites for different enzymes and adaptors which contain phosphotyrosine-binding (PTB) or Src homology 2 (SH2) domains (Roskoski, 2007) .
For example, the recruitment of PLC1 to activated VEGFR2 stimulates hydrolysis of plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP 3 ) (Koch et al., 2011; Roskoski, 2007) .
Production of IP 3 activates IP 3 receptors on the sarcoplasmic reticulum leading to a rise in cytosolic calcium ion levels. DAG activation of protein kinase C (PKC) activates the MAPK pathway. PKC also phosphorylates MEK resulting in phosphorylation and activation of p42/44 MAPK (ERK1/2), transcriptional upregulation of angiogenic genes and increased cell proliferation. The Shb adaptor molecule also binds to activated and tyrosine phosphorylated VEGFR2, stimulating phosphatidylinositol 3-kinase (PI3K) to activate downstream master regulator and serine/threonine protein kinase, Akt. Activation of endothelial Akt triggers activation of endothelial nitric oxide synthase (eNOS) promoting nitric oxide production, vascular permeability and vasodilation (Koch et al., 2011; Roskoski, 2007) . Nitric oxide stimulates the expression and transcriptional activity of the HIF-1 transcription activator, which upregulates VEGF-A mRNA synthesis and provides a further link between eNOS and angiogenesis (Karar and Maity, 2011) . Another regulatory protein, T-cell-specific adaptor (TSAd) can be recruited to VEGFR2 via the VEGFR2-pY1175 epitope and stimulates recruitment and activation of the c-Src proto-oncogene and tyrosine kinase, resulting in increased endothelial cell migration and vascular permeability. Sequential activation of CDC42, p38 MAPK and heat shock protein 27 following recruitment to the VEGFR2-pY1214 epitope stimulates cell migration and actin remodeling. Generation of the VEGFR2-pY1214 epitope is also linked to increased focal adhesion turnover (Koch et al., 2011; Roskoski, 2007) .
Following VEGF-A activation, VEGFR2 is endocytosed and trafficked through the endosome-lysosome system followed by recycling back to the plasma membrane or degradation. A model for VEGFR2 trafficking was suggested proposing that VEGFR2 undergoes constitutive clathrin-dependent endocytosis with recycling from early endosomes (Bruns et al., 2010) . Upon VEGFR2 binding to VEGF-A 165a the rate of endocytosis is increased as VEGFR2 phosphorylation, ubiquitination and proteolysis is linked to trafficking into late endosomes and lysosomes. Rab GTPases are members of the Ras superfamily of GTPases and regulate many aspects of membrane trafficking and organelle fusion. Internalization of receptors from the plasma membrane into early endosomes requires Rab5a (Jopling et al., 2009 ).
Depletion of Rab5a increases VEGFR2 phosphorylation and MAPK signaling.
Additionally, over-expressing the Rab5a GTPase deficient and constitutively active Q79L mutant causes accumulation of VEGFR2 in enlarged endosomes (Bruns et al., 2009; Jopling et al., 2009) . Another member of the Rab family, Rab7a, is involved in the transport of VEGFR2 and other proteins from early to late endosomes (Bruns et al., 2009 ). Depletion of Rab7a decreases the level of detectable phosphorylated VEGR2 but increases MAPK signaling (Bruns et al., 2009; Jopling et al., 2009 ).
Over-expression of either the Rab7a GDP-bound dominant negative mutant (T22N) or a GTP-bound constitutively active mutant (Q67L) causes accumulation of VEGFR2 within late endosomes (Bruns et al., 2009; Jopling et al., 2009 ).
Additionally, depletion of Rab5a or Rab7a showed that Rab GTPase levels either had a stimulatory or inhibitory effect on endothelial cell migration respectively (Bruns et al., 2009; Jopling et al., 2009) . Redirection of activated VEGFR2 from early to late endosomes suggests that specific compartments could regulate VEGFR2 signaling; this view is strengthened by the fact that a MAPK scaffold associates with endosomes and is required for full ERK1/2 activation (Santambrogio et al., 2011) .
VEGFR2 undergoes constitutive endocytosis and recycling at a rate of 0.14 min -1 (Santambrogio et al., 2011) and is delivered into intracellular EEA1-positive, Rab5a-positive early endosomes before being transported back to the plasma membrane by a Rab4-dependent regulatory step in recycling endosomes (Gampel et al., 2006; Santambrogio et al., 2011) . This novel endosomal recycling compartment is independent of another recycling pathway involving Rab11-positive endosomes but is dependent on c-Src tyrosine kinase activity (Gampel et al., 2006 ).
Vascular models
Primary endothelial cells are one of the few cell types that express relatively high levels of VEGFR2 and their capacity for both physiological and pathological angiogenesis make them ideal model systems to study endothelial receptor-ligand complex regulation. VEGFR2-VEGF-A activation and signaling modulates endothelial cell migration, proliferation, tubulogenesis and apoptosis. All of these outcomes can be replicated using different techniques and assays for the growth of defined primary endothelial cells used to study signaling pathways and effectors involved in a variety of cellular responses.
Endothelial cell characterization
Introduction
Primary human umbilical vein endothelial cells (HUVECs) provide a physiologically relevant cell type for studying VEGF-A. Here we describe methods for isolating and validating HUVECs. HUVECs can be retrieved from fresh (~3-18 h old) umbilical cords (~20 cm in length) by digestion of the lumen of the large umbilical vein with collagenase, purified and cultured at 37˚C in a humidified 5% (v/v) CO 2 atmosphere (Howell et al., 2004; Jaffe et al., 1973) . HUVECs exhibit a characteristic 'cobblestone' morphology ( Figure 1A ) and can be validated by labeling for the endothelial-specific marker proteins platelet endothelial cell adhesion molecule (PECAM-1 or CD31), vascular endothelial (VE)-cadherin and Von Willebrand factor (VWF) ( Figure 1B-1D ) and VEGFR2 ( Figure 1E ) using immunofluorescence microscopy or flow cytometry. VEGFR2 expression is characteristic of endothelial cells whereas VEGFR1 is more widely expressed ( Figure 1F Cannulate the vein with a blunt-ended sterile needle attached to a 20 ml syringe.
Flush with pre-warmed (37˚C) PBS (phosphate-buffered saline) containing penicillin (100 units/ml), streptomycin (100 μg/ml) and amphotericin B (50 μg/ml) until all blood and clots are removed.
2. Using a hemostat, clamp the umbilical cord at one end and perfuse the vein with~10 ml of serum-free MCDB131 medium (Invitrogen, Amsterdam, Netherlands), containing 0.1% (w/v) type II-S collagenase from Clostridium histolyticum (SigmaAldrich, Poole, UK), until full before clamping the other end.
3. Incubate the clamped cord for at 37˚C for 20 min.
4. Unclamp the vein carefully at one end, placing it within a sterile 50 ml screw cap plastic centrifuge tube. Unclamp the other end and using a 20 ml syringe as before, flush extensively with PBS containing penicillin (100 units/ml), streptomycin (100 μg/ml) and amphotericin B (50 μg/ml). Collect all dislodged cellular material (up to a total volume of 50 ml) within the sterile tube. 6. Resuspend cell pellet in 6-8 ml of pre-warmed (37˚C) Endothelial Cell Growth Medium (ECGM) supplemented with 2% (w/v) fetal calf serum (FCS), recombinant epidermal growth factor (EGF, 5 ng/ml), hydrocortisone (0.2 g/ml), recombinant basic fibroblast growth factor (bFGF, 10 ng/ml), recombinant long insulin-like growth factor 1 (IGF-1, 20 ng/ml), ascorbic acid (1 g/ml) and heparin (22.5g/ml) (Promocell, Heidelberg, Germany 
Rab GTPase depletion using RNAi
Note: these working volumes are per 75 cm 2 flask; however, they can be scaled up or down.
1. For RNAi treatment of a single confluent 75 cm 2 flask, prepare a solution of 4 ml antibiotic-and serum-free OptiMEM medium (Invitrogen) containing 240 pmol siRNA duplex and 32 μl Lipofectamine RNAiMAX transfection reagent (Invitrogen).
2. Invert briefly to mix components and incubate at room temperature for 20 min. 5. Incubate at 37°C for 6 h.
6. Remove Optimem/siRNA media and replace with 10 ml pre-warmed ECGM.
7. Culture cells at 37°C for 48-72 h prior to assays for receptor function and endothelial cell responses. 11. Mix cells with Trypan Blue (Invitrogen) and determine cell number using a hemocytometer.
12. Transfer cells to a 50 ml centrifuge tube and pellet cells at 200 g for 5 min.
13. Aspirate supernatant and resuspend cells at desired concentration in appropriate growth media.
14. Seed HUVECs into gelatin-coated tissue culture plates, multi-well plates and coverslips for further experiments.
15. Process cells for analysis of VEGFR2 signaling and trafficking (Section 4) or endothelial cell responses (Sections 5-6).
Quantification of Rab GTPase depletion using RNAi
To quantify Rab GTPase depletion, protein levels are detected using immunoblotting. Take a sample containing 5x10 4 -1x10 5 cells when seeding transfected HUVECs and compare them to non-transfected cells.
1. Pellet cells at 200 g for 5 min. Remove and discard supernatant.
2. Add 250 l 2% (w/v) SDS containing 1 mM protease inhibitor cocktail (SigmaAldrich) to lyse the cells. Gently invert the tube a few times to mix the lysate. This should become a highly viscous but clear solution.
3. Transfer cell lysate to 1.5 ml microcentrifuge tube.
4. Boil lysate at 95°C for 5 min and sonicate for 3 sec at 13-15 microns using a Soniprep 150 probe sonicator (Sanyo, Osaka, Japan).
5. Briefly centrifuge the cell lysate.
6. Determine protein concentration of samples using the bicinchoninic acid assay (BCA).
7. Aliquot 25-50 g of cell lysate into a 1. 10. Subject cell lysate to denaturing SDS-PAGE on a 6-16% gradient gel at 120 V at room temperature for 1-2 h.
11. Transfer proteins onto reinforced 0.2 m pore size nitrocellulose membrane at 300 mA at 4°C for 3 h or at 30 mA at 4°C overnight (16-24 h).
12. Incubate membranes briefly in Ponceau S (1 g/l Ponceau in distilled water containing 5% (v/v) glacial acetic acid). Rinse off excess dye using distilled water and check for the presence of polypeptides transferred onto membrane.
13. Rinse off Ponceau S stain using TBS-T (20 mM Tris pH7.6, 137 mM NaCl containing
14. Block non-specific antibody binding by incubating membrane in 5% non-fat milk in TBS-T at room temperature for 30 min. In non-stimulated endothelial cells, VEGFR2 localizes in early endosomes, the Golgi and plasma membrane (Bruns et al., 2009; Jopling et al., 2011; Manickam et al., 2011 or chemically fix the samples for microscopy (see step 10).
6. Centrifuge cell lysates at 16 000 g at 4°C for 30 min. Discard pellet and store lysates on ice.
7. Incubate remaining samples at 37°C in serum-free MCDB131 medium for varying lengths of time to allow internalization of biotinylated cell surface receptor-ligand complexes.
8. Remove exposed cell surface biotin label by using 3 sequential 10 min incubations in buffer containing 100 mM sodium 2-mercaptoethansulfonate (MESNA), 50 mM Tris pH 8.6, 100 mM NaCl, 1 mM EDTA, 0.2% (w/v) BSA.
9. Quench the reaction using 120 mM iodoacetamide in PBS.
10. Fix and process cells for microscopy (see Section 2.2.3) or lyse in an isotonic NP-40 lysis buffer.
11. For receptor recycling analysis, subject cells to a second incubation at 37°C for 20 min in serum-free MCDB131 medium prior to a second round of MESNA washes.
12. Lyse cells, centrifuge lysates and determine protein concentrations using the BCA assay. 3. After incubation, chill on ice and remove bound cell surface antibody by acid washing cells twice in ice-cold MCDB131 medium adjusted to pH 2.0.
4. Wash cells twice in ice-cold MCDB131 medium at standard pH.
5. Incubate cells with a species-specific fluorescently conjugated secondary antibody (in PBS) at 37°C for 1 h. Remove surface bound antibody by acid wash as previously described.
Fix cells and visualize VEGFR2 localization by immunofluorescence microscopy.
Only proteins which have recycled at least 1.5 times are visible by microscopy.
Analysis of VEGF-A-stimulated signaling events
Changes in signaling pathways can be monitored by detection of post-translational modifications (e.g. phosphorylation) on key signaling proteins (VEGFR2, Akt, eNOS, MAPK) whose total levels are also simultaneously quantified using SDS-PAGE and immunoblot analysis.
1. Culture HUVECs until confluent in gelatin-coated 6-well plates.
Aspirate media and wash once in PBS.
3. Serum starve cells in MCDB131 medium containing 0.2% (w/v) BSA at 37°C for 3 h.
4. Stimulate cells with 25 ng/ml VEGF-A for desired time course.
Lyse cells in 100 l lysis buffer (2% (w/v) SDS, phosphatase cocktail, protease inhibitor cocktail in PBS).
6. Transfer lysates into 1.5 ml microcentrifuge tubes.
7. Boil lysates at 92°C for 5 min. Sonicate for 3 sec using a tip probe sonicator set at 10-15 microns.
8. Briefly centrifuge cell lysates.
9. Determine protein concentration using the BCA assay.
10. Aliquot 25-50 g of cell lysate into a 1.5 ml microcentrifuge tube. Add required amount of 2X SDS-PAGE sample buffer to each sample.
11. Briefly centrifuge the cell lysate. Samples can now be stored at -20°C before analysis.
12. Load 25-50 g of protein lysate on a 10% SDS-PAGE gel and carry out immunoblot analysis as previously described (see 3.3) using primary antibodies against desired signaling node.
13. Visualize signal from immunoblot using a sensitive CCD-based imaging workstation e.g. Fuji LAS-3000 (Fuji, Japan) with analysis software e.g. AIDA (Fuji, Japan) ( Figure 2 ).
14. Quantify band intensity using analysis software and compare VEGF-A-stimulated protein levels to non-stimulated control levels. Note: blotting for a housekeeping protein such as actin or tubulin acts as an internal control for variations in sample loading. Dividing the value for protein of interest intensity by the tubulin or actin intensity standardizes loading.
Endothelial cell responses
Introduction VEGF-A modulates vasculogenesis and angiogenesis by regulating specific
endothelial cell responses such as cellular proliferation, migration and viability.
Cellular proliferation is regulated by the ERK, p38 and Akt signalling nodes (Horowitz and Seerapu, 2012; Liu et al., 2006) . These pathways are activated downstream of VEGFR2 upon stimulation with VEGF-A (Olsson et al., 2006) . Disruption of VEGFR2 endosomal signalling and proteolysis was shown to regulate the levels of ERK1/2
and Akt activation respectively (Bruns et al., 2009; Bruns et al., 2010; Jopling et al., 2009 ) which impacts on cellular outputs such as cell proliferation. A simple and effective assay for evaluating cell proliferation is by monitoring the incorporation of the pyrimidine 5-bromo-2'-deoxyuridine (BrdU) analog into newly synthesized DNA (instead of thymidine) using a non-radioactive, ELISA-like colorimetric assay.
The early stages of angiogenesis and vasculogenesis depend heavily on endothelial cell migration (Carmeliet, 2005; Schmidt et al., 2007) . Our lab has shown that disruption of VEGFR2 trafficking and proteolysis in the endosome-lysosome system perturbs VEGF-A-stimulated cell migration (Bruns et al., 2009; Jopling et al., 2009 ). Additionally, VEGF-A also regulates endothelial cell viability and apoptosis (Gerber et al., 1998) . This section provides a subset of cellular assays to determine the effect that blocking endosomal signalling has on cell outcome.
Cell proliferation
Note: we recommend using a cell proliferation ELISA kit (Roche Diagnostics, Burgess Hill, UK). This protocol is optimized for use of this cell proliferation ELISA kit and reagents provided within. The length of incubation times may need optimization for non-kit reagents. 11. Repeat steps 9-10 twice more to give a total of three washes.
12. Add 100 μl per well of substrate solution (3,3′,5,5′-Tetramethylbenzidine, TMB) and incubate at room temperature for 5-30 min until color change is sufficient for photometric detection. Measure absorbance routinely after 10-30 min at 370 or 650 nm using a multiwell plate absorbance reader. 14. Measure the absorbance immediately at 450 nm using a multiwell plate absorbance reader.
Cell migration
The endothelial cell migration assay was carried out using 8 μm pore size polyester membrane (Transwell) inserts from BD Biosciences (Oxford, UK). 11. Remove Transwell filter and rinse by gentle submersion into a beaker of PBS.
12. Remove cells from the upper (internal) side of the filter using a cotton bud.
13. Leave filters at room temperature overnight and allow to dry completely.
14. View the membrane using a digital microscope system with low power (4X, 10X) and high power (60X) objective lenses. Collect 3-5 random field images (containing no more than 100 cells per image to reduce counting errors) per membrane ( Figure 3A) . 
Apoptosis and cell cycle analysis
Flow cytometry is a convenient technique to evaluate endothelial cell apoptosis or DNA content. In contrast to previous techniques that detect cell surface membrane receptors using antibody-based labeling, probes are used to label non-protein molecules. In one case, a phospholipid, phosphatidyleserine (PS), is exposed at the extracellular/exposed leaflet of the plasma membrane lipid bilayer upon mammalian cell commitment to apoptosis or programmed cell death (Fadok et al., 1992) . This can be monitored using Annexin V which binds to PS in the presence of calcium ions (Koopman et al., 1994) . The cellular DNA content is also substantially altered during states such as interphase, mitosis or apoptosis. This change in DNA content can also be monitored using flow cytometry by monitoring the binding of a fluorescent DNA-binding dye to endothelial cell DNA. 11. Aspirate supernatant and resuspend pellet in 0.5 ml of 100 g/ml ribonuclease, 50 g/ml propidium iodide in PBS. Incubate at 37°C for 3 h.
12. Pellet cells by centrifugation at 200 g at room temperature for 5 min.
13. Carefully remove and discard supernatant. Gently resuspend cell pellet in 1 ml of PBS.
14. Run samples on a Fortessa flow cytometer set to run at a low flow rate (12-60 l per min) and analyze data using ModFit software (Becton Dickinson).
Tubulogenesis
Introduction
A functional assay which evaluates endothelial cell capacity to form vascular tubes in vitro is the endothelial-fibroblast co-culture assay (Bishop et al., 1999) . In this assay, primary endothelial cells (HUVECs) are seeded on a confluent layer of normal human dermal foreskin fibroblasts (HFF) and cultured for 7-10 days, depending on growth conditions, media and treatments. One important advantage of this assay is that other assays employing biological matrices (e.g. Collagen, Matrigel) also promote growth of multicellular/tubular structures of non-vascular cells e.g.
fibroblasts, epithelial cells. However, this co-culture assay appears restricted in its specificity in promoting endothelial tube formation (tubulogenesis) within a heterogeneous cellular population (Beilmann et al., 2004; Donovan et al., 2001) .
Tubulogenesis is an essential feature in the phenomenon of angiogenesis. This organotypic angiogenesis assay has been used to evaluate the action of small molecule tyrosine kinase inhibitors on VEGF-A-stimulated responses (Kankanala et al., 2012; 6.2. Organotypic angiogenesis assay 
Summary
The VEGF-A cytokine was originally identified by its ability to modulate vascular function in mammals. In the past 20 years, the complexity of this gene family has been vastly increased by the discovery of multiple genes in mammals (VEGF-A, -B, -C, -D, PlGF), viral orthologs (VEGF-E) and snake venoms (VEGF-F) (Koch et al., 2011; Ponnambalam and Alberghina, 2011; Ruiz de Almodovar et al., 2009 ). Many of these genes encode multiple splice variants whose functions remain obscure.
Genetic ablation of VEGFs is invariably lethal during early embryogenesis, making it difficult to evaluate gene function in different tissues and organs. Of note, VEGFs have been increasingly implicated in epithelial and neuronal function, suggesting that these cytokines have a much wider regulatory function than anticipated. This highlights the need for studies within this area using different cell-based systems to decode the biological activity of the VEGF superfamily.
There is increasing evidence that VEGF-A-dependent signaling and proangiogenic outcomes are regulated by receptor-ligand trafficking and processing through the endosome-lysosome system. Regulators of receptor-mediated endocytosis (Bruns et al., 2010; Ewan et al., 2006) , endosome-linked Rab GTPases (Gampel et al., 2006; Jopling et al., 2009; Reynolds et al., 2009 ) and endosomeassociated ubiquitination machinery (Ewan et al., 2006; Hasseine et al., 2007) regulate VEGF-A-stimulated downstream signaling pathways. Ablation of specific regulators linked to different membrane compartments in which a VEGFR complex is located could delineate specific signaling and cell response outcomes associated with temporal and spatial distribution of the receptor-ligand complex. In this way, one can determine how different biological signals are generated in time and space upon receptor binding to a specific ligand e.g. VEGF-A.
A major challenge is to evaluate the role of a complex series of enzymes including GTPases and ubiquitin ligases in modulating response to VEGF-A through VEGFR2. Different studies suggest a role for Rab5a in regulating VEGFR2 trafficking through early endosomes (Jopling et al., 2009) , whereas evidence suggests a role for Rab4a and/or Rab11a in recycling from endosomes (Gampel et al., 2006; Reynolds et al., 2009) . The Rab7a GTPase associated with late endosomes regulates VEGFR2 trafficking towards final degradation in lysosomes (Jopling et al., 2009) . Intriguingly, VEGFR2 is also trafficked slowly through the secretory pathway with evidence for a SNARE-regulated mechanism in controlling its transit through the Golgi apparatus (Manickam et al., 2011) . The role of ubiquitination in VEGFR2 function is contradictory: although early studies suggested a role for the E3 ubiquitin ligase c-Cbl (Duval et al., 2003) ; more recent studies suggest roles for different E3 ubiquitin ligases (Bruns et al., 2010; Meyer et al., 2011; Murdaca et al., 2004) .
Notably, another receptor tyrosine kinase such as epidermal growth factor receptor (EGFR/ErbB1) exhibits both mono-and polyubiquitination upon ligand binding and activation (Haglund and Dikic, 2012; Haglund et al., 2003; Huang and Sorkin, 2005; Sorkin and Goh, 2009 ). Different endosome-associated ubiquitin ligases and deubiquitinases could thus fine tune cellular responses to a receptor-ligand complex depending on its residence time within a specific compartment and final proteolysis of the ubiquitinated membrane receptor.
The VEGFR-VEGF axis is of much interest in understanding vascular function but is also implicated in tumor neovascularization, arterial repair and regeneration after heart attacks and strokes. Our work provides a suite of techniques and assays to stimulate further work in this area and related fields such as neurobiology. Such assays can be easily adapted towards studies in primary and transformed epithelial, neuronal and immune cells, systems that are likely to respond to other VEGF splice variants or family members. Increasingly, VEGF dysfunction is implicated in conditions such as amyotrophic lateral sclerosis (motor neuron disease), multiple sclerosis and Alzheimer's Disease (Ponnambalam and Alberghina, 2011) .
Deciphering the role of a specific VEGFR-VEGF complex in a cellular and tissuespecific context will not only shed light on basic mechanisms of receptor signaling and function but also on possible therapeutic strategies in a wide variety of ailments.
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